Company research / Focus view

Zydus Lifesciences

ZYDUSLIFE · Pharma & Healthcare · large cap · Nifty Next 50

Revenue

—

What the business sold · not collected yet

Net profit

—

What it kept after tax · not collected yet

Operating profit

—

Profit from operations · not collected yet

Operating cash flow

—

Cash the operations produced · not collected yet

Total debt

—

Borrowings against the business · not collected yet

Dividend per share

—

Paid out per share · not collected yet

Five years in perspective

Price index · Start = 100 · Dividends excluded · ₹1,119.1 today (+0.12%)

+102.8% · 5Y

2021 · 10020222023202420252026 · 222.6

1M -3.6%6M +28.5%1Y +14.0%3Y +82.0%5Y +102.8%

Market cap

₹1.12 L Cr

As of 12 Sept 2026

Price to earnings

24.9

Price to book 4.2

Dividend yield

9.00%

Trailing twelve months

52-week range

₹836 – ₹1,205

Closing prices

The financial record

₹ crore · Consolidated where reported · Indian fiscal years (April–March)

Annual figures arrive with the daily research run; earlier years with the filings backfill.

Recent quarters

₹ crore · Most recent first

Quarter ended	Revenue	Operating profit	Net profit	EPS (₹)
30 Jun 2026	7,802	1,318	940	9.35
31 Mar 2026	7,434	1,401	1,273	12.65
31 Dec 2025	6,780	1,292	1,042	10.36
30 Jun 2025	6,467	1,793	1,467	14.58
31 Mar 2025	6,290	1,927	1,171	11.64

Developments

2 positive · 0 negative

Neutral3 days ago

Zydus Lifesciences: Credit Ratings Reaffirmed at ‘AAA/Stable’ and ‘A1+’

Zydus Lifescienceslarge cap

InvestyWise11 Sept 2026, 3:40 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Zydus Lifesciences to participate in J.P. Morgan India Conference on September 21

Zydus Lifescienceslarge cap GAIL (India)Mentioned

scanx.trade11 Sept 2026, 12:23 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralExpansion4 days ago

Zydus launches new #LiverKiSuno campaign to spotlight silent liver health risks

Zydus Lifescienceslarge cap

Social Samosa10 Sept 2026, 2:42 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Biocon Ltd Share Price Today,, BIOCON Share Price NSE, BSE

Zydus Lifescienceslarge cap BSE LtdMentioned

Business Today10 Sept 2026, 12:30 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads positiveRevenue4 days ago

Zydus, Glenmark lead pharma growth in August; semaglutide generics sales rise 2%: Nomura

Zydus Lifescienceslarge cap

Moneycontrol.com10 Sept 2026, 12:17 pm IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.85. This is not the probability that the report is true.

Neutral4 days ago

CURIS LIFESCIENCES Share Price: 9.63% Fall Analysis

Zydus Lifescienceslarge cap

Univest10 Sept 2026, 10:55 am IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralExpansion5 days ago

India’s Pharma Market Grows 10.7% in August as GLP-1 Launches Boost Growth

Zydus Lifescienceslarge cap GAIL (India)Mentioned

Voice of Healthcare9 Sept 2026, 6:11 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

Zydus Lifesciences Share Price Fall: Pharma Stock Analysis

Zydus Lifescienceslarge cap

Univest9 Sept 2026, 3:14 pm IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralExpansion5 days ago

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

Zydus Lifescienceslarge cap GAIL (India)Mentioned

NDTV Profit9 Sept 2026, 1:59 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

‘Show me’ market: UltraGreen.ai should ditch its share buybacks for proactive engagement

Zydus Lifescienceslarge cap

The Business Times9 Sept 2026, 5:42 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral6 days ago

Zydus Lifesciences - Supreme Industries among 4 stocks showing RSI trending up

Zydus Lifescienceslarge cap Supreme IndustriesMentioned

The Economic Times8 Sept 2026, 1:12 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral6 days ago

Zydus Lifesciences' US Arm Agrees to Pay USD 5.9 Mn to Settle Generic Drug Pricing Litigation

Zydus Lifescienceslarge cap

Medical Dialogues8 Sept 2026, 10:30 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral6 days ago

Syrma SGS Technology among 4 stocks showing White Marubozu Pattern

Zydus Lifescienceslarge cap

The Economic Times8 Sept 2026, 9:30 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

Nifty Pharma Today: Up 0.75% to 26,675.50

Zydus Lifescienceslarge cap

Univest7 Sept 2026, 4:15 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

HEG Advanced Materials, ESDS, Maruti Suzuki, Zydus Wellness among buzzing stocks as NIFTY, SENSEX down 0.6%

Apollo Hospitalslarge cap Maruti Suzuki IndiaMentioned Zydus LifesciencesMentioned

Upstox7 Sept 2026, 1:37 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

Zydus Lifesciences Share Price Today: market cap and peers

Zydus Lifescienceslarge cap

Univest7 Sept 2026, 11:56 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

Zydus Wellness up 8%, PVR Inox down 7%: Check out other Nifty 500 top movers - CNBC TV18

PVR INOXsmall cap Zydus LifesciencesMentioned

LinkedIn7 Sept 2026, 11:20 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads positive7 days ago

Volumes jump at Zydus Wellness Ltd counter

Bajaj Holdings & Investmentlarge cap Zydus LifesciencesMentioned

Business Standard7 Sept 2026, 11:04 am IST

Classification & context · Routine

The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.85. This is not the probability that the report is true.

Neutral7 days ago

Zydus Wellness up 8%, PVR Inox down 7%: Check out other Nifty 500 top movers

Manappuram Financesmall cap PVR INOXMentioned Zydus LifesciencesMentioned

CNBC TV187 Sept 2026, 10:05 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

About the business

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Industry: Drug Manufacturers - Specialty & Generic

zyduslife.com

Data confidence

Prices, fundamentals and developments last verified 12 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.

See the Pharma & Healthcare sector →

Sign in to see the full financial record and classified developments

Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.